2015
DOI: 10.1517/21678707.2015.1030393
| |Summarize |Cite
|
Sign up to set email alerts

Improvement in vision: a new goal for treatment of hereditary retinal degenerations

Abstract: Introduction: Inherited retinal degenerations (IRDs) have long been considered untreatable and incurable. Recently, one form of early-onset autosomal recessive IRD, Leber congenital amaurosis (LCA) caused by mutations in RPE65 (retinal pigment epithelium-specific protein 65 kDa) gene, has responded with some improvement of vision to gene augmentation therapy and oral retinoid administration. This early success now requires refinement of such therapeutics to fully realize the impact of these major scientific an… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
19
6
2
0

Citation Types

0
18
0
0

Year Published

Range
2016
2016
2024
2024

Publication Types

Select...
21
3
2
1

Relationship

1
26

Authors

Journals

Cited by 27 publications

(18 citation statements)

References 77 publications

0
18
0
0
Order By: Relevance
How the paper below cites the one you are viewing
“…For the same reason, even the use of fixed reference values of total retinal thickness, such as the thickness of the central subfield >100 μm considered for patients eligible for Luxturna therapy, should not be considered unequivocal proof of the presence of photoreceptors [ 27 ] but should always be used to assess their functionality. In fact, experimental evidence shows that degeneration can proceed even after patients have been treated, suggesting that there has been a certain threshold of photoreceptor loss in these patients [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ]. For this reason, the loss of approximately 30% of the normal complement of photoreceptors is a therapeutic prerequisite with Luxturna, a threshold beyond which treatment will not have the desired outcome, with the progression of retinal degeneration occurring [ 33 , 59 ].…”
Section: Discussion
mentioning
confidence: 99%
“…For this reason, the loss of approximately 30% of the normal complement of photoreceptors is a therapeutic prerequisite with Luxturna, a threshold beyond which treatment will not have the desired outcome, with the progression of retinal degeneration occurring [ 33 , 59 ]. In fact, it is possible that locally preserved photoreceptors may continue to degenerate after treatment when the similarly treated neighboring retina has already exceeded the threshold for continued degeneration [ 62 , 63 ]. Another contraindication to Luxturna treatment is the presence of detectable photoreceptors that lack a relatively conserved supporting RPE, as the basic abnormalities in RPE65 -IRD, which are the primary cellular target of gene transfer, reside in this layer [ 64 ].…”
Section: Discussion
mentioning
confidence: 99%
See 1 more Smart Citation